Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Scripps Institute starts "first" large study of gene testing's effects

This article was originally published in Clinica

Executive Summary

The Scripps Translational Science Institute in San Diego, California, has started a trial to assess the impact of genetic testing. The study, co-sponsored by Navigenics, Affymetrix and Microsoft, will analyse the DNA of up to 10,000 Scripps Health hospital employees, family members and friends, and will track changes in their behaviour over the next 20 years. Affymetrix (Santa Clara, California) will scan each participant's genome and Navigenics (Redwood Shores, California) will interpret the results and offer personalised guidance. Scripps plans to report the first results in April or May 2009, about three months after the tests. Participants will be questioned about their subsequent lifestyle changes, including diet, exercise and smoking. Earlier this month, experts questioned the role of gene testing, saying they could cause unnecessary stress (see Clinica No 1324, p 30).

You may also be interested in...

What are the hottest innovations from Israel?

Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.

EuroPCR: St Jude and Philips talk up rival intravascular imaging techs

St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.

EuroPCR: Medtronic's drug-coated balloon keeps rising

A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts